AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12086758 — intervention group
Group type: COMPARATOR
Intervention: Non-HAART
Number of subjects: 1034
Study 9565058 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green staining of the anterior capsule
Number of subjects: 20
Study 9565058 — intervention group
Group type: COMPARATOR
Intervention: Standard circular continuous capsulorrhexis
Number of subjects: 20
Study 7622910 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1ra)
Number of subjects: 0
Study 7622910 — intervention group
Group type: COMPARATOR
Intervention: Escherichia coli infusion
Number of subjects: 0
Study 2694741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxim (1.5 g intravenous bolus at the beginning of and 12 hours after the operation)
Number of subjects: 80
Study 2694741 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous bolus at the beginning of and 12 hours after the operation)
Number of subjects: 80
Study 375684 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (60 mg daily for four weeks)
Number of subjects: 50
Study 31153659 — intervention group
Group type: COMPARATOR
Intervention: Advice alone
Number of subjects: 756
Study 31153659 — intervention group
Group type: EXPERIMENTAL
Intervention: Established lifestyle intervention (physical activity, sodium reduction, weight loss)
Number of subjects: 756
Study 31153659 — intervention group
Group type: EXPERIMENTAL
Intervention: Established + DASH lifestyle intervention (DASH diet counseling)
Number of subjects: 756
Study 31153659 — intervention group
Group type: EXPERIMENTAL
Intervention: Every 10-session increase in counseling
Number of subjects: 756
Study 28550081 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifediol (5000 IU 25-hydroxyvitamin D3), thrice weekly for 6 months
Number of subjects: 119
Study 28550081 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 µg 1,25-dihydroxyvitamin D3), thrice weekly for 6 months
Number of subjects: 119
Study 28550081 — intervention group
Group type: COMPARATOR
Intervention: Placebo, thrice weekly for 6 months
Number of subjects: 119
Study 28550081 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vitamin D treatment (calcifediol and calcitriol)
Number of subjects: 119
Study 28550081 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vitamin D treatment
Number of subjects: 119
Study 26560487 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 4-hydroxytamoxifen (4-OHT) gel applied daily to the axillary mammary gland for 6 weeks
Number of subjects: 0
Study 26560487 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal endoxifen gel applied daily to the axillary mammary gland for 6 weeks
Number of subjects: 0
Study 26560487 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal telapristone acetate gel
Number of subjects: 0
Study 26560487 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac patch applied to the breast skin
Number of subjects: 0
Study 26560487 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac patch applied to the abdominal skin
Number of subjects: 0
Study 23379344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional microplasma RF
Number of subjects: 33
Study 23379344 — intervention group
Group type: COMPARATOR
Intervention: CO2 FS
Number of subjects: 33
Study 21184267 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora-administered educational intervention
Number of subjects: 381
Study 21184267 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 381
Study 19361781 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving training (PST) intervention group
Number of subjects: 64
Study 19361781 — intervention group
Group type: COMPARATOR
Intervention: Education-only control group
Number of subjects: 64
Study 17708377 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tech (Duo2, Hill Rom) alternating low-pressure mattress
Number of subjects: 203
Study 17708377 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tech (Duo2, Hill Rom) continuous low-pressure mattress
Number of subjects: 203
Study 17708377 — intervention group
Group type: COMPARATOR
Intervention: High-specification foam mattress (control)
Number of subjects: 203
Study 17708377 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tech mattress (alternating vs continuous low pressure)
Number of subjects: 203
Study 15020517 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatrial pacing
Number of subjects: 23
Study 15020517 — intervention group
Group type: COMPARATOR
Intervention: High right atrial pacing (HRA)
Number of subjects: 23
Study 15020517 — intervention group
Group type: COMPARATOR
Intervention: Coronary sinus pacing (CS)
Number of subjects: 23
Study 10799369 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (4 g daily)
Number of subjects: 59
Study 10799369 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (4 g daily)
Number of subjects: 59
Study 10799369 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EPA and DHA (4 g daily)
Number of subjects: 59
Study 10799369 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 59
Study 8831316 — intervention group
Group type: COMPARATOR
Intervention: T 0.5% + E (control group)
Number of subjects: 60
Study 8831316 — intervention group
Group type: EXPERIMENTAL
Intervention: T 1% + E
Number of subjects: 60
Study 8831316 — intervention group
Group type: EXPERIMENTAL
Intervention: T 0.5%
Number of subjects: 60
Study 8831316 — intervention group
Group type: EXPERIMENTAL
Intervention: T 1%
Number of subjects: 60
Study 1388336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil bolus dose (30 micrograms/kg) followed by bolus doses of 10 micrograms/kg every 10 min
Number of subjects: 40
Study 1388336 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alfentanil infusion (30 micrograms/kg induction dose over 1 min, followed by infusion at 1.0 micrograms.kg‐1.min‐1)
Number of subjects: 40
Study 1388336 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 40
Study 1388336 — intervention group
Group type: COMPARATOR
Intervention: Incisional procedures
Number of subjects: 40
Study 3888943 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus mezlocillin
Number of subjects: 60
Study 31367909 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose exercise (8 kcal/kg body weight/week)
Number of subjects: 137
Study 31367909 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose exercise (20 kcal/kg body weight/week)
Number of subjects: 137
Study 31367909 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise groups (moderate and high-dose)
Number of subjects: 137
Study 31367909 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compensators (participants who lost more weight)
Number of subjects: 137
Study 31367909 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2peak increase
Number of subjects: 137
Study 31367909 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 137
Study 29509911 — intervention group
Group type: EXPERIMENTAL
Intervention: LIDΔM2‐2 vaccine (105 PFU, single intranasal dose)
Number of subjects: 29
Study 29509911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29509911 — intervention group
Group type: EXPERIMENTAL
Intervention: LIDΔM2‐2 vaccine
Number of subjects: 29
Study 28832514 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado (0.5 mg/day lutein)
Number of subjects: 40
Study 28832514 — intervention group
Group type: COMPARATOR
Intervention: Control (potato or chickpeas, 0 mg/day lutein)
Number of subjects: 40
Study 28832514 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado
Number of subjects: 40
Study 28832514 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 28832514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 26655803 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.06 mcg.kg(1).min(‐1))
Number of subjects: 81
Study 26655803 — intervention group
Group type: COMPARATOR
Intervention: Levosimendan (0.2 mcg.kg(1).min(‐1))
Number of subjects: 81
Study 23379292 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (20 U)
Number of subjects: 276
Study 23379292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 20663998 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 20
Study 20663998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17693592 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance-based quality improvement intervention
Number of subjects: 29
Study 17693592 — intervention group
Group type: COMPARATOR
Intervention: Paper-based education
Number of subjects: 29
Study 17693592 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 29
Study 17052490 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5% hydrogel/clindamycin 1% lotion + UVA irradiation
Number of subjects: 45
Study 17052490 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone 0.05% cream + UVA irradiation
Number of subjects: 45
Study 12709680 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral folic acid per day
Number of subjects: 81
Study 12709680 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg oral folic acid per day
Number of subjects: 81
Study 12709680 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated patients (5 mg and 15 mg)
Number of subjects: 81
Study 12709680 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 81
Study 10781752 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 5
Study 10781752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 8827136 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifuge subjects exposed to 15 s rapid onset (6 G.s‐1) + 5 Gz exposure while wearing a well‐fitting anti‐G suit (pressure inactivated)
Number of subjects: 0
Study 8827136 — intervention group
Group type: COMPARATOR
Intervention: Tilt/LBNP group (upright tilt and lower body negative pressure at -20 mm Hg and -40 mm Hg)
Number of subjects: 0
Study 8827136 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifuge subjects at G-LOC endpoints
Number of subjects: 0
Study 1571611 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) administered within 8 hours of injury
Number of subjects: 487
Study 1571611 — intervention group
Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 487
Study 1571611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 3907988 — intervention group
Group type: EXPERIMENTAL
Intervention: sulindac (200 mg twice daily)
Number of subjects: 312
Study 3907988 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 312
Study 31246603 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic haloperidol (1 or 2 mg)
Number of subjects: 1789
Study 31246603 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 1789
Study 30251914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) treatment (14-16J/cm2) combined with Meibomian Gland Expression (MGX)
Number of subjects: 0
Study 30251914 — intervention group
Group type: COMPARATOR
Intervention: Sham IPL treatment (0J/cm2)
Number of subjects: 0
Study 27344439 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (subcutaneous 200 IU/kg once daily during month 1, followed by 150 IU/kg once daily for months 2-6)
Number of subjects: 676
Study 27344439 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA) (once daily for 6 months, with initial overlapping subcutaneous dalteparin 200 IU/kg once daily for ≥5 days until INR was 2.0-3.0 for 2 consecutive days)
Number of subjects: 676
Study 27344439 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 676
Study 27344439 — intervention group
Group type: COMPARATOR
Intervention: VKA
Number of subjects: 676
Study 24873096 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal turn‐down group
Number of subjects: 48
Study 24873096 — intervention group
Group type: COMPARATOR
Intervention: Palmaris longus tendon graft group
Number of subjects: 48
Study 22551881 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-vitamin D3 fixed combination
Number of subjects: 610
Study 22551881 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D3 separate combination
Number of subjects: 610
Study 22551881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 20861210 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenols (PP) 50 mg
Number of subjects: 17
Study 20861210 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenols (PP) 200 mg
Number of subjects: 17
Study 20861210 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole bean porridge with PP and PA removal
Number of subjects: 17
Study 20861210 — intervention group
Group type: EXPERIMENTAL
Intervention: PP removal from dephytinized porridge
Number of subjects: 17
Study 20861210 — intervention group
Group type: EXPERIMENTAL
Intervention: Dephytinization in the absence of PP
Number of subjects: 17
Study 19073970 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy
Number of subjects: 527
Study 16387150 — intervention group
Group type: EXPERIMENTAL
Intervention: DAC-7 (daunorubicine + cytarabine + cladribine)
Number of subjects: 66
Study 16387150 — intervention group
Group type: COMPARATOR
Intervention: DA-7 (daunorubicine + cytarabine without cladribine)
Number of subjects: 66
Study 16387150 — intervention group
Group type: EXPERIMENTAL
Intervention: DAC-7
Number of subjects: 66
Study 16387150 — intervention group
Group type: EXPERIMENTAL
Intervention: DAC-7 and DA-7
Number of subjects: 66
Study 12819407 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (group 1, G1)
Number of subjects: 83
Study 12819407 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (group 2, G2)
Number of subjects: 83
Study 10625567 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (topical analgesia cream)
Number of subjects: 12
Study 10625567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7965421 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed diet (group MD) containing rice, chicken, carrots, beans, and vegetable oil
Number of subjects: 87
Study 7965421 — intervention group
Group type: COMPARATOR
Intervention: Lactose-free, soy protein isolate formula (group SF)
Number of subjects: 87
Study 2888658 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg mifentidine
Number of subjects: 10
Study 31532004 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-based feeding protocol (VP)
Number of subjects: 227
Study 31532004 — intervention group
Group type: COMPARATOR
Intervention: Conventional hourly rate method (CM)
Number of subjects: 227
Study 29466786 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 50,000 IU every 2 weeks for 6 months
Number of subjects: 58
Study 29466786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 26516810 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic (AC) treatment
Number of subjects: 243
Study 26516810 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) treatment
Number of subjects: 243
Study 27371428 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-PDT (Indocyanine green photodynamic therapy) with 0.1% ICG lotion applied for 30 minutes and long pulse diode laser, 3 treatments over 2 weeks
Number of subjects: 47
Study 27371428 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-PDT (Indocyanine green photodynamic therapy) with 0.1% ICG lotion applied for 30 minutes and long pulse diode laser, 5 treatments over 2 weeks
Number of subjects: 47
Study 23896389 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspase-3 and caspase-9 expression in Group 3 (DM and DR)
Number of subjects: 60
Study 23896389 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspase-3 and caspase-9 expression in Group 2 (DM without DR)
Number of subjects: 60
Study 23896389 — intervention group
Group type: COMPARATOR
Intervention: Caspase-3 and caspase-9 expression in Group 1 (no DM)
Number of subjects: 60
Study 21764028 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline TIMI grade 3 flow
Number of subjects: 5332
Study 21764028 — intervention group
Group type: EXPERIMENTAL
Intervention: Final TIMI grade 3 flow
Number of subjects: 5332
Study 18849616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster SIT (14 injections of house dust mite allergen within 6 weeks)
Number of subjects: 34
Study 18849616 — intervention group
Group type: COMPARATOR
Intervention: Classic SIT (14 injections of house dust mite allergen within 14 weeks)
Number of subjects: 34
Study 18849616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster SIT
Number of subjects: 34
Study 18849616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster SIT and Classic SIT
Number of subjects: 34
Study 17093147 — intervention group
Group type: EXPERIMENTAL
Intervention: 11trans-18:1 and 12trans-18:1 supplementation (3.0 g each per day for 6 weeks)
Number of subjects: 24
Study 17093147 — intervention group
Group type: COMPARATOR
Intervention: Control oil free of trans fatty acids and conjugated linoleic acids
Number of subjects: 24
Study 15269141 — intervention group
Group type: EXPERIMENTAL
Intervention: hTERT:540-548 peptide emulsified in incomplete Freund's adjuvant
Number of subjects: 14
Study 15269141 — intervention group
Group type: EXPERIMENTAL
Intervention: hTERT:540-548 peptide
Number of subjects: 14
Study 11692118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of epinephrine into the thigh
Number of subjects: 0
Study 11692118 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of epinephrine into the upper arm
Number of subjects: 0
Study 11692118 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of epinephrine into the upper arm
Number of subjects: 0
Study 10554767 — intervention group
Group type: EXPERIMENTAL
Intervention: IUGR pregnancies
Number of subjects: 19
Study 10554767 — intervention group
Group type: COMPARATOR
Intervention: Control pregnancies
Number of subjects: 19
Study 10554767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate dehydrogenase release
Number of subjects: 19
Study 7646942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger taken prior to 8‐MOP
Number of subjects: 0
Study 7646942 — intervention group
Group type: COMPARATOR
Intervention: 8‐MOP without ginger
Number of subjects: 0
Study 2816804 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counseling (intervention group)
Number of subjects: 0
Study 2816804 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 73792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 44
Study 73792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 31553500 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource loss
Number of subjects: 312
Study 31553500 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily stressors
Number of subjects: 312
Study 31553500 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of relocation experiences
Number of subjects: 312
Study 31553500 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial resource loss
Number of subjects: 312
Study 31553500 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 312
Study 31553500 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower educational status
Number of subjects: 312
Study 31077124 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 40
Study 31077124 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 40
Study 31077124 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine and prone positions
Number of subjects: 40
Study 31077124 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance from left common iliac artery to anterior contour of L4/L5 intervertebral disc
Number of subjects: 40
Study 28888618 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized feedback intervention to doctors; patients rated their perception of the doctor's quality of care using an 8-question feedback card.
Number of subjects: 379
Study 28888618 — intervention group
Group type: COMPARATOR
Intervention: Control group with no feedback intervention.
Number of subjects: 379
Study 25542920 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of exercise at baseline
Number of subjects: 342
Study 25542920 — intervention group
Group type: COMPARATOR
Intervention: Low levels of exercise at baseline
Number of subjects: 342
Study 25542920 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial changes in exercise
Number of subjects: 342
Study 23064476 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg of alendronate and 0.5-µg of calcitriol (Maxmarvil®)
Number of subjects: 98
Study 23064476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 22141229 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia-based FDPs
Number of subjects: 45
Study 22141229 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia frameworks
Number of subjects: 45
Study 22141229 — intervention group
Group type: COMPARATOR
Intervention: Periodontal health
Number of subjects: 45
Study 19920054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (200 mg intravenous iron)
Number of subjects: 459
Study 19920054 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 459
Study 16491287 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium- and vitamin D3-fortified milk (400 ml/day providing 1000 mg calcium and 800 IU vitamin D3)
Number of subjects: 167
Study 16491287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional milk)
Number of subjects: 167
Study 12760893 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin (800 mg once daily)
Number of subjects: 0
Study 12760893 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanic acid (1 g of amoxicillin and 125 mg of clavulanic acid 3 times daily)
Number of subjects: 0
Study 10690692 — intervention group
Group type: EXPERIMENTAL
Intervention: New low-dose warfarin induction regimen
Number of subjects: 120
Study 10690692 — intervention group
Group type: COMPARATOR
Intervention: Modified Fennerty regimen
Number of subjects: 120